This presentation will describe regulatory considerations for biomarker development. Topics will include 1) the process for the FDA biomarker qualification program for biomarkers to be used in drug development, 2) FDA guidance on technical performance assessment of quantitative imaging in radiological device premarket submissions, and 3) the role of consensus statements from professional societies to support the regulatory process.
